HC Wainwright Has Negative Forecast for KALV FY2028 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for shares of KalVista Pharmaceuticals in a research report issued on Friday, March 27th. HC Wainwright analyst A. Fein now expects that the specialty pharmaceutical company will earn $2.06 per share for the year, down from their prior estimate of $2.25. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

A number of other equities research analysts have also issued reports on KALV. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Stifel Nicolaus upped their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Citizens Jmp reduced their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday. Needham & Company LLC boosted their price target on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

KalVista Pharmaceuticals Stock Performance

KALV opened at $19.33 on Monday. KalVista Pharmaceuticals has a 12-month low of $9.23 and a 12-month high of $19.95. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock has a market capitalization of $990.08 million, a PE ratio of -4.89 and a beta of -0.35. The firm’s fifty day moving average price is $16.04 and its 200 day moving average price is $14.45.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently modified their holdings of KALV. Emerald Advisers LLC lifted its position in KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after purchasing an additional 313,205 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $24,360,000. Jefferies Financial Group Inc. acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth approximately $3,494,000. Blue Owl Capital Holdings LP acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth approximately $1,522,000. Finally, Stonepine Capital Management LLC grew its holdings in KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,130,000 after buying an additional 78,450 shares in the last quarter.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the completion of the transaction, the insider directly owned 138,983 shares in the company, valued at $2,163,965.31. This represents a 3.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Nicole Sweeny sold 3,975 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the completion of the sale, the insider directly owned 47,003 shares in the company, valued at $731,836.71. This represents a 7.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 248,009 shares of company stock valued at $4,213,467. 4.30% of the stock is owned by insiders.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.